Genetic Technologies Limited
GENE · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | $9,762 | $21,046 | $25,819 | $80,669 |
| - Cash | $1,021 | $7,851 | $11,731 | $20,902 |
| + Debt | $875 | $533 | $653 | $204 |
| Enterprise Value | $9,617 | $13,728 | $14,740 | $59,970 |
| Revenue | $7,665 | $10,348 | $6,795 | $121 |
| % Growth | -25.9% | 52.3% | 5,536.3% | – |
| Gross Profit | $3,904 | $6,013 | $6,474 | -$240 |
| % Margin | 50.9% | 58.1% | 95.3% | -199.5% |
| EBITDA | -$11,431 | -$11,203 | -$7,201 | -$6,583 |
| % Margin | -149.1% | -108.3% | -106% | -5,460.7% |
| Net Income | -$12,017 | -$11,751 | -$7,131 | -$7,078 |
| % Margin | -156.8% | -113.6% | -104.9% | -5,870.9% |
| EPS Diluted | -2.73 | -3.6 | -2.32 | -2.48 |
| % Growth | 24.2% | -55.2% | 6.5% | – |
| Operating Cash Flow | -$9,679 | -$9,723 | -$5,659 | -$6,296 |
| Capital Expenditures | -$33 | -$18 | -$97 | -$642 |
| Free Cash Flow | -$9,712 | -$9,741 | -$5,756 | -$6,938 |